Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the stock.

Several other research analysts have also recently weighed in on CTLT. Royal Bank of Canada restated a sector perform rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Barclays boosted their target price on Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research report on Friday, June 28th. Finally, William Blair reissued a market perform rating on shares of Catalent in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Hold and an average target price of $58.08.

Catalent Stock Performance

Shares of CTLT opened at $59.69 on Tuesday. Catalent has a 52 week low of $31.80 and a 52 week high of $61.20. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The business’s 50 day moving average price is $59.09 and its 200-day moving average price is $57.09. The stock has a market cap of $10.80 billion, a P/E ratio of -9.79, a P/E/G ratio of 2.14 and a beta of 1.15.

Insider Buying and Selling at Catalent

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares in the company, valued at $1,921,840.54. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,409 shares of company stock valued at $782,923. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Catalent by 1.1% during the first quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock worth $1,151,872,000 after acquiring an additional 218,682 shares during the last quarter. Capital World Investors boosted its stake in Catalent by 6.1% during the fourth quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after buying an additional 1,098,474 shares during the period. Nomura Holdings Inc. increased its position in Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock valued at $516,126,000 after acquiring an additional 6,881,914 shares during the last quarter. Cadian Capital Management LP raised its stake in shares of Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after acquiring an additional 759,600 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.